http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2065083-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76ba102ea9c02b6633d64bf09c5b89a4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 |
| filingDate | 1992-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53b81252e3fa24ad5bb51e602f3bfaeb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e3b55c3316a9953c49d00b93f63efa9 |
| publicationDate | 1992-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2065083-A1 |
| titleOfInvention | Topical 5-fluorouracil prodrug composition and method |
| abstract | "TOPICAL 5-FLUOROURACIL PRODRUG COMPOSITION AND METHOD" ABSTRACT OF THE DISCLOSURE A pharmaceutical composition in unit dosage form adapted for topical administration to a human or non-human animal in need thereof comprising a pharmacologically affec-tive amount of a prodrug of 5-fluorouracil having the formula: wherein: R1 and R2 may be the same or different and are selected from the group consisting of H, R3CO- and R4-O-CO with the proviso that both R1 and R2 may not be H; or a non-toxic pharmaceutically acceptable salt, adduct, oxide or other derivative thereof; a pharmaceutically acceptable, topically administrable carrier therefor; and a method for topically applying the composition. R3 and R4 comprise groups such that the prodrug (1) has an enhanced delivery across topical membranes and (2) hydrolyzes after delivery to 5-fluorouracil. |
| priorityDate | 1991-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.